Saturday, November 27, 2021

NEWS

Bumetanide shows potential as Alzheimer’s disease treatment

Bumetanide shows potential as Alzheimer’s disease treatment

Washington, Oct 14 (Prensa Latina) A team of experts said that Bumetanide -a commonly used and potent oral diuretic pill- may provide an expected yet efficacious treatment for those at genetic risk of Alzheimer's disease, as funded by the National Institute of Aging (NIA).
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

The research illuminated that people taking bumetanide, which is approved by the US Food and Drug Administration (FDA), had a significantly lower prevalence of Alzheimer’s disease than those not taking the drug.

Subsequently, the team examined the APOE4-specific Alzheimer’s signatures against those of over 1,300 drugs approved by the FDA, of which five demonstrated a gene expression signature that had the potential to neutralise the disease. The most promising of the final candidates was bumetanide, a diuretic employed to remedy fluid retention incurred by medical problems such as kidney, heart, and liver disease.

To further authenticate the potential of the drug signified by the data-driven testing, the team performed examinations of bumetanide on mouse models with Alzheimer’s and induced stem-cell-derived human neurons, finding that the diuretic reduced memory and learning deficits in mice expressing the human APOE4 gene. .

These results were further validated in the human cell-based models, indicating that there should be lower rates of Alzheimer’s in people who were already taking bumetanide.

mh/pll/msm/joe

RELATED
ÚLTIMO MINUTO
name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.